Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 17 Oct 2023 for NEOGEN CORP, €5,030. Read the official filing
Filing timeline
BuySaleJason Warren Lilly
Insider track record
Disclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jason Warren Lilly: trading record in brief
Jason Warren Lilly (chief executive) discloses dealings in Neogen Corp to SEC (Form 4). Over a trading history stretching from 3 May 2021 to 13 October 2023, the count stands at 6 filings.
Sales make up the whole of the open-market record (3 sales, €61k). Outside the open market, there are 1 share grant and 2 option exercises. 2023 to date brings no purchases and 2 sales.
The newest entry dates from 17 October 2023: an open-market sale of €5,030, in Neogen Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jason Warren Lilly
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
351 shares@ US$15.100.7% of flowCommon StockSEC:0000711377-23-000014:0
1,917 shares@ US$15.69494.1% of flowCommon StockSEC:0000711377-23-000011:0
388 shares@ US$16.670.9% of flowCommon StockSEC:0000711377-23-000008:0
636 shares@ US$31.350.0014% mcap2.7% of flowCommon StockSEC:0000711377-21-000035:0
15,998 shares@ US$20.231376.7% of flowCommon StockSEC:0000711377-21-000021:0
350 shares@ US$96.737.7% of flowCommon StockSEC:0000711377-21-000018:0
6 of 6 declarations
